111In-DOTA-dPhe1-Tyr3-octreotide, 111In-DOTA-lanreotide and 67Ga citrate scintigraphy for visualisation of extranodal marginal zone B-cell lymphoma of the MALT type: a comparative study

  • Shuren Li
  • Amir Kurtaran
  • Mei Li
  • Tatjana Traub-Weidinger
  • Oskar Kienast
  • Wolfgang Schima
  • Peter Angelberger
  • Irene Virgolini
  • Markus Raderer
  • Robert Dudczak
Original Article


Somatostatin receptor (SSTR) scintigraphy and gallium-67 citrate (67Ga) scintigraphy have been used for visualisation of Hodgkin's lymphoma and non-Hodgkin's lymphoma. However, experience with B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) type is very limited. The aim of this study was to prospectively compare the 67Ga scintigraphy results with those obtained by 111In-DOTA-dPhe1-Tyr3-octreotide (111In-DOTA-TOCT) and 111In-DOTA-lanreotide (111In-DOTA-LAN) scintigraphy in patients with proven MALT-type lymphoma. Comparative scintigraphic examinations using 67Ga, 111In-DOTA-TOCT and 111In-DOTA-LAN were performed in 18 patients (11 female and 7 male, median age 64±15 years) with histologically verified MALT-type lymphomas of various origin. Planar and single-photon emission tomography imaging acquisitions were performed after injection of a mean dose of 185±26 MBq 67Ga and 165±20 MBq 111In-DOTA-TOCT or 111In-DOTA-LAN. All scintigraphic results were correlated with other conventional examinations including gastroscopy, colonoscopy, endosonoscopy, ophthalmologic investigation, CT of the thorax and abdomen and bone marrow biopsy. This comparative study showed that 67Ga scintigraphy found abnormalities in 10 of 16 patients (63%) and detected 18 of 31 clinically involved sites (58%), but was false positive in three patients. 111In-DOTA-TOCT found abnormalities in 9 of 15 patients (60%) and detected 15 of 27 clinical lesions (56%); it was false positive in two patients. 111In-DOTA-LAN scintigraphy showed abnormalities in 7 of 11 patients (64%) and found 12 of 22 clinical lesions (55%). False-positive 111In-DOTA-LAN scan results were found in two patients. For supra-diaphragmatic lesions, 67Ga scintigraphy detected 12 of 16 sites (75%). 111In-DOTA-TOCT scintigraphy revealed 7 of 15 lesions (47%). 111In-DOTA-LAN showed 6 of 12 positive sites (50%). For infra-diaphragmatic involvement, the sensitivities of 67Ga, 111In-DOTA-TOCT and 111In-DOTA-LAN were 40%, 67% and 60%, respectively. It is concluded that MALT-type lymphoma can be visualised by 67Ga, 111In-DOTA-TOCT and 111In-DOTA-LAN scintigraphy. Although there were no statistically significant differences in patient-related and site-related sensitivities when using 67Ga compared with 111In-DOTA-TOCT and 111In-DOTA-LAN, the sensitivity of 67Ga tended to be superior to that of 111In-DOTA-TOCT and 111In-DOTA-LAN for supra-diaphragmatic lesions but inferior for infra-diaphragmatic involvement. In selected cases, the combination of 67Ga and 111In-DOTA-LAN or 111In-DOTA-TOCT may increase the diagnostic efficiency in patients with MALT-type lymphoma.


Somatostatin receptor scintigraphy Gallium scintigraphy MALT-type lymphoma 



We are grateful for the financial support of the Dr. Pfeiffer Scholarship of the Austrian Society of Nuclear Medicine and the Jubilaeumsfonds of the Austrian Nationalbank (Project Nr. 8320). We would like to thank Mrs. K. Wiesner and P. Schaffarich for their technical assistance. This paper is also dedicated to my dear son, Suoyu Li († January 19, 2003).


  1. 1.
    Isaacson PG, Wright DH. Malignant lymphoma of mucosal associated lymphoid tissue: a distinctive type of B cell lymphoma. Cancer 1983; 52:1410–1416.PubMedGoogle Scholar
  2. 2.
    Isaacson PG, Norton AJ. Mucosa associated lymphoid tissue (MALT) and the MALT-lymphoma concept. In: Isaacson PG, Norton AJ, eds. Extranodal lymphomas. Edinburgh: Churchill-Livingstone; 1994:5–14.Google Scholar
  3. 3.
    Thieblemont C, Bastion Y, Berger F, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Oncol 1997; 15:1624–1630.PubMedGoogle Scholar
  4. 4.
    Taal BG, Burgers JM, van Heerde P, et al. The clinical spectrum and treatment of primary non-Hodgkin's lymphoma of the stomach. Ann Oncol 1993; 4:839–846.PubMedGoogle Scholar
  5. 5.
    Raderer M, Vorbeck F, Formanek M, et al. Importance of extensive staging in patients with mucosa-associated lymphoid tissue (MALT)-type lymphoma. Br J Cancer 2000; 83:454–457.PubMedGoogle Scholar
  6. 6.
    van den Anker-Lugdenburg PJ, Lowenberg B, Lamberts SW, et al. The relevance of somatostatin receptor expression in malignant lymphomas. Metabolism 1996; 45:96–97.PubMedGoogle Scholar
  7. 7.
    Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002; 32:84–91.CrossRefPubMedGoogle Scholar
  8. 8.
    De Jong M, Bakker WH, Krenning EP, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of DOTA-Phe1-Tyr3-octreotide a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med 1997; 24:368–371.Google Scholar
  9. 9.
    Breeman WA, de Jong M, Kwekkeboom DJ, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001; 28:1421–1429.PubMedGoogle Scholar
  10. 10.
    Raderer M, Valencak J, Pfeffel F, et al. Somatostatin receptor expression in primary gastric versus nongastric extranodal B-cell lymphoma of mucosa-associated lymphoid tissue type. J Natl Cancer Inst 1999; 91:716–718.CrossRefPubMedGoogle Scholar
  11. 11.
    Raderer M, Traub T, Formanek M, et al. Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type. Br J Cancer 2001; 85:1462–1466.CrossRefPubMedGoogle Scholar
  12. 12.
    Lugtenburg PJ, Lowenberg B, Valkema R, et al. Somatostatin receptor scintigraphy in the initial staging of low-grade non-Hodgkin's lymphomas. J Nucl Med 2001; 42:222–229.PubMedGoogle Scholar
  13. 13.
    Gallamini A, Biggi A, Fruttero A, et al. Revisiting the prognostic role of gallium scintigraphy in low-grade non-Hodgkin's lymphoma. Eur J Nucl Med 1997; 24:1499–1506.Google Scholar
  14. 14.
    Delcambre C, Reman O, Henry-Amar M, et al. Clinical relevance of gallium-67 scintigraphy in lymphoma before and after therapy. Eur J Nucl Med 2000; 27:176–184.PubMedGoogle Scholar
  15. 15.
    Fukumoto M, Kurohara A, Akagi N, et al. Ga-67 visualization of the coexistence of two mucosa-associated lymphoid tissue (MALT) lymphomas in the thyroid and stomach. Clin Nucl Med 1998; 23:484.CrossRefPubMedGoogle Scholar
  16. 16.
    Ben-Haim S, Bar-Shalom R, Israel O, et al. Utility of gallium-67 scintigraphy in low-grade non-Hodgkin's lymphoma. J Clin Oncol 1996; 14:1936–1942.PubMedGoogle Scholar
  17. 17.
    Rohatiner A, d'Amore F, Coiffier B, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol 1994; 5:397–400.PubMedGoogle Scholar
  18. 18.
    Smith-Jones PM, Bischof C, Leimer M, et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999; 140:5136–5148.PubMedGoogle Scholar
  19. 19.
    Virgolini I, Patri P, Novotny C, et al. Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr3-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy. Ann Oncol 2001; 12 (Suppl 2):S41–S45.Google Scholar
  20. 20.
    Pileri SA, Milani M, Fraternali-Orcioni G, et al. From the R.E.A.L. Classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities? Ann Oncol 1998; 9:607–612.CrossRefPubMedGoogle Scholar
  21. 21.
    Hoffmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-d-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol 1999; 10:1185–1189.CrossRefPubMedGoogle Scholar
  22. 22.
    Stomper PC, Cholewinski SP, Park J, et al. Abdominal staging of thoracic Hodgkin disease: CT-lymphangiography-Ga-67 scanning correlation. Radiology 1993; 187:381–386.PubMedGoogle Scholar
  23. 23.
    Reubi JC, Schar JC, Waser B, et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27:273–282.PubMedGoogle Scholar
  24. 24.
    Virgolini I, Traub T, Novotny C, et al. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 2002; 8:1781–1807.PubMedGoogle Scholar
  25. 25.
    Ferreri AJ, Ponzoni M, Cordio S, et al. Low sensitivity of computed tomography in the staging of gastric lymphomas of mucosa-associated lymphoid tissue: impact on prospective trials and ordinary clinical practice. Am J Clin Oncol 1998; 21:614–616.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Shuren Li
    • 1
  • Amir Kurtaran
    • 1
  • Mei Li
    • 1
  • Tatjana Traub-Weidinger
    • 1
  • Oskar Kienast
    • 1
  • Wolfgang Schima
    • 1
    • 3
  • Peter Angelberger
    • 4
  • Irene Virgolini
    • 5
    • 6
  • Markus Raderer
    • 2
  • Robert Dudczak
    • 1
    • 6
  1. 1.Department of Nuclear MedicineUniversity of ViennaViennaAustria
  2. 2.Department of Internal Medicine I, Division of OncologyUniversity of ViennaAustria
  3. 3.Department of RadiodiagnosticsUniversity of ViennaAustria
  4. 4.Research Center SeibersdorfAustria
  5. 5.Institute for Nuclear MedicineVienna Hospital LainzAustria
  6. 6.Ludwig-Boltzman Institute for Nuclear MedicineViennaAustria

Personalised recommendations